RodneyPRocconiMD

Gynecologic Oncology

Professor of Gynecologic Oncology, University of Alabama at Birmingham Associate Director, Infirmary Cancer Care Director of Research, Infirmary Cancer Care Specializing in preventing, diagnosing, and treating gynecological cancers

Join to view full profile

Dr. Rocconi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rocconi's full profile

Already have an account?

Office
1660 Springhill Avenue
Mobile, AL 36640
Phone+1 251-410-1010

Fax+1 251-665-8010

Summary

Dr. Rodney P. Rocconi is a Gynecologic Oncologist, specializing in preventing, diagnosing and treating gynecological cancers. He completed a Fellowship at the University of Alabama at Birmingham in Birmingham, AL. He is an Associate Director for Clinical Research

Rodney P. Rocconi, M.D., F.A.C.O.G. | USA Health

Rodney P. Rocconi, M.D., joined Mitchell Cancer Institute (MCI) as a physician-scientist in the Gynecologic Oncology Service in 2007. He was the first MCI Abrah

Education & Training

University of Alabama Medical CenterResidency, Obstetrics and Gynecology, 2000 - 2004
University of Alabama School of MedicineClass of 2000
University of Alabama Medical CenterFellowship, Gynecologic Oncology

Certifications & Licensure

MS State Medical License 2023 - 2025
AL State Medical License 2001 - 2024
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
Active, not recruiting
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer Start of enrollment: 2100 Jan 01
Not yet recruiting
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Start of enrollment: 2012 Jan 09
Completed
Phase 3
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2011 Dec 12
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
Manoj Sonavane, Jenna Hedlich-Dwyer, Valeria L Dal Zotto, Min Tang, John Nemunaitis
Gynecologic Oncology. 2024-11-14
A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
Annelise M Wilhite, Sharon Wu, Joanne Xiu, Geoffrey T Gibney, Thuy Phung
Gynecologic Oncology. 2024-09-01
Racial, ethnic and country of origin disparities in aggressive endometrial cancer histologic subtypes.
Stuart S Winkler, Chunqiao Tian, Yovanni Casablanca, Nicholas W Bateman, Suzanne Jokajtys
Gynecologic Oncology. 2024-05-01

Press Mentions

Gradalis to Host Key Opinion Leader Webinar on Unmet Medical Needs in Ovarian Cancer and the Company’s Immuno-Oncology Treatment, Vigil®September 28th, 2022
14th Annual GO Run 5K Stays Virtual for 2021August 17th, 2021
Vaccine Maintenance Improves Relapse-Free Survival in BRCA Wild-Type Ovarian CancerMay 6th, 2020
Join now to see all